Qnovia’s smoking cessation asset QN-01 shows superior pharmacokinetic profile in Phase 1 trial
The Phase 1 open-label trial studied the delivery of QN-01 via the RespiRx device for three different nicotine…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Dec 23
The Phase 1 open-label trial studied the delivery of QN-01 via the RespiRx device for three different nicotine…
01 Dec 23
The funding will accelerate the manufacturing and distribution of Mytos' automated cell production system to more biotech and…
29 Nov 23
Avidity will receive an upfront payment of $100m and is eligible to receive up to $1.35bn in research…
29 Nov 23
V116 is an investigational, 21-valent vaccine, currently in late-stage trial for prevention of invasive pneumococcal disease and pneumococcal…
29 Nov 23
AWS will help Amgen discover, develop, and boost the production throughput of medicines and increase sustainability and operational…
29 Nov 23
Collaboration focused on discovering oral inhibitors of protein-protein interaction (PPI) targets by leveraging PRISM BioLab's proprietary PepMetics technology
28 Nov 23
The FDA approval is based on positive data from the Phase 3 DeFi trial, in which Ogsiveo significantly…
28 Nov 23
ARCT-032 has been designed to use the firm’s LUNAR lipid-mediated aerosolised platform to provide CFTR messenger RNA to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Nov 23
In the trial, Dupixent reduced moderate or severe acute COPD exacerbations by 34% over 52 weeks and led…
28 Nov 23
The drug achieved the primary endpoint of progression-free survival and extended the time to disease progression or death…